Journals / Güncel Pediatri / 2012 / Cilt: 10 - Sayı: 3

Diagnostic criteria of growth hormone deficiency needs to be reevaluated

Büyüme hormonu eksikliğinin tanı kriterleri yeniden değerlendirilmelidir

Pages
74–79
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Height SDS significantly increased after the first and second years of GH treatment (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: In this study, we aimed to investigate the factors that determine response to growth hormone (GH) treatment in children with isolated idiopathic GH deficiency treated in our university hospital.
📊
Key Findings & Data:Materials and Methods: The data of 149 patients followed in our university hospital between January 1995 and December 2005 were evaluated in patient charts retrospectively.
💡
Conclusion & Impact:Height SDS significantly increased after the first and second years of GH treatment (p
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: In this study, we aimed to investigate the factors that determine response to growth hormone (GH) treatment in children with isolated idiopathic GH deficiency treated in our university hospital. Materials and Methods: The data of 149 patients followed in our university hospital between January 1995 and December 2005 were evaluated in patient charts retrospectively. Results: The maximum GH response to clonidine and glucagon stimulation tests was 4.58 and 6.01 ng/ml respectively. The mean GH dose was 0.215 (0.18-0.25) mg/kg/week. Height SDS significantly increased after the first and second years of GH treatment (p

Özet

Girifl: Bu çalışmada, hastanemizde büyüme hormonu (BH) eksikliği tanısıyla izlenen çocuklarda tedaviye yanıtı belirleyen etkenlerin belirlenmesi amaçlanmıştır. Gereç ve Yöntem: İzole idyopatik BH eksikliği nedeniyle takip edilen ve BH tedavisi kullanan toplam 149 hastanın verileri retrospektif olarak incelendi. Bulgular: Tanı aşamasında bakılan ortalama maksimum BH yanıtı klonidin stimülasyon testi için 4,58 ng/ml, glukagon stimülasyon testi için ise 6,01 ng/ml bulundu. Ortalama BH dozu 0,215 (0,18-0,25) mg/kg/hafta olarak belirlendi. BH tedavisi ile boy SDS anlamlı olarak arttı (p

🔖

Cite This Article

SAĞLAM, H., TARIM, Ö., SALI, E. (2022). Diagnostic criteria of growth hormone deficiency needs to be reevaluated. Güncel Pediatri, Cilt: 10 - Sayı: 3, 74–79. https://ajindex.com/articles/528015

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Allen DB, Johanson AJ, Blizzard RM: Growth hormone treatment; In Lifshitz F (ed): Pediatric Endocrinology. 3rd edition. New York: Marcel Dekker; 1996. 61-81
  2. Guyda HJ. Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab 1999;84:4307-16
  3. Bundak R, Hindmarsh PC, Brook CG. Long-term auxologic effects of human growth hormone. J Pediatr 1988;112:875-9
  4. Coste J, Letrait M, Carel JC, Tresca JP, Chatelain P, Rochiccioli P, et al. Long term results of growth hormone treatment in France in children of short stature: population, register based study. BMJ 1997;315:708-13
  5. Ranke MB, Price DA, Albertsson-Wikland K, Maes M, Lindberg A. Factors determining pubertal growth and final height in growth hormone treatment of idiopathic growth hormone deficiency. Analysis of 195 Patients of the Kabi Pharmacia International Growth Study. Horm Res 1997;48:62-71
  6. Cole TJ, Hindmarsh PC, Dunger DB. Growth hormone (GH) provocation tests and the response to GH treatment in GH deficiency. Arch Dis Child 2004;89:1024-7
  7. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 1999;84:1174-83
  8. Nathan BM, Allen DB. Growth Hormone Treatment. In: Lifshitz F (eds). Pediatric Endocrinology. 5rd edition. New York: Informa; 2007:113-43
  9. Greulich WW, Pyle SI, (eds) Radiographic atlas of skeletal development of the hand and wrist. Second edition, Stanford University Press; 1959
  10. Neyzi O, Günöz H, Furman A, Bundak R, Gökçay G, Darendeliler F, et al. Türk çocuklarında vücut ağırlığı, boy uzunluğu, baş çevresi ve vücut kitle indeksi referans değerleri. Çocuk Sağlığı ve Hastalıkları Dergisi 2008;51:1-14
  11. Lifshitz F, Botero D. Growth and growth disorders In: Lifshitz F. (eds). Pediatric Endocrinology. 4rd edition. Newyork: Marcel- Dekker; 2004:1-18
  12. Chatelain P. Trends in the diagnosis and treatment of short stature as revealed by KIGS In: Ranke MB and Wilton P (eds): Growth Hormone Therapy in KIGS 10 Years Experience. Heidelberg: Leipzig: Barth J&J;1999. 11-20
  13. Reiter EO, Rosenfeld RG. Normal and aberrant growth In: Wilson ID, Foster DW, Kronenberg HM, Larsen PR (eds): Williams Text Book of Endocrinology.